Fenbendazole treatment of pregnant bitches to reduce prenatal and lactogenic infections of Toxocara canis and Ancylostoma caninum in pups

A granulated formulation of fenbendazole was tested in a total of 23 treated and control, pregnant, parasite-free Beagle bitches experimentally infected with Toxocara canis and Ancylostoma caninum. The drug was administered to each treated bitch once daily in canned dog food at a dosage of 50 mg/kg body weight. Each of 2 treatment regimens tested was initiated on the 40th day of pregnancy. One regimen involved daily treatment continuing through the 14th postpartum day, and it resulted in 89% fewer ascarids and 99% fewer hookworms in pups born to medicated bitches, as compared with pups born to unmedicated controls. The other regimen of treatment, which was stopped on the day of parturition, was less effective in reducing ascarid and hookworm burdens (64% and 88% reductions, respectively). Three to 5 bitches from each of the treatment and control groups were allowed to whelp a 2nd litter without further treatment or further exposure to parasite infections. Hookworm burdens in 2nd-litter pups born of bitches that had initially received fenbendazole through the 14th postpartum day were significantly lower (P < 0.01; 85% reduction), when compared with the 2nd-litter control pups. All other parasite burdens were not significantly different. It was concluded that granulated fenbendazole is effective in reducing burdens of Ancylostoma caninum and Toxocara canis in newborn pups when the bitch is treated during the last third of pregnancy, especially when treatment (50 mg/kg/day) extends from the 40th day of pregnancy through the 14th postpartum day.     

Comparison of plasma aldosterone concentration among clinical status groups of dogs with chronic heart failure

The plasma aldosterone concentration (PAC) among clinical status groups of 23 dogs with chronic heart failure was compared at various times after diagnosis of the problem. Eighteen dogs admitted in New York Heart Association (NYHA) class IV clinical status had significant elevations in PAC (P<0.0001), when compared with clinically normal dogs. Five dogs admitted in NYHA class III status and 4 dogs that responded with a change to NYHA class III status had significant elevations in PAC (P<0.01), when compared with clinically normal dogs. In patients with NYHA class IV status, the PAC was significantly greater (P<0.01) than in patients in NYHA class III status. For patients with the poorest prognosis, ie, severe signs of NYHA class IV status, the PAC was not markedly different, when compared with that for patients with a favorable prognosis, ie, recent onset of signs of NYHA class IV status. Patients treated with captopril had significantly lower PAC after therapy (P<0.01), whereas patients treated with hydralazine had significantly higher PAC (P<0.05) after therapy. It was concluded that heart failure in the dog increases PAC, most likely because of renin-angiotensin-aldosterone-system activation, and that the increase is related directly to the clinical status of the patient. Further, it was concluded that treatment of dogs in heart failure with captopril causes a decrease in circulating PAC, whereas treatment with hydralazine causes an increase in circulating PAC.     

Equine herpesvirus abortion in Australia 1977 to 1982

Until 1977 no case of abortion caused by equine herpesvirus 1 (EHV1) had been recorded in Australia although the virus, called equine rhinopneumonitis virus, had been known to have been present at least since 1962. Outbreaks of EHV1 abortion occurred in New South Wales in 1977 and in 1981. Sporadic cases of EHV1 abortion had been confirmed in some parts of Australia each year since 1975. It was concluded that an abortigenic subtype of EHV1 had been introduced to Australia in 1977 and that the previously endemic respiratory subtype occasionally caused abortion. Virus isolation in a variety of cell cultures and histopathological examination of tissue were shown to be satisfactory methods of diagnosis of EHV1 abortion. Lung proved to be the specimen of choice. Slight serological differences between "abortigenic" and "respiratory" subtypes of EHV1 were found in cross neutralisation tests. A serological survey of 219 Sydney horses of various ages revealed that most yearlings had already acquired neutralising antibody to both subtypes.     

Kinematics of the equine thoracolumbar spine

At least three types of movement take place in the joint complexes of the equine thoracolumbar spine: dorsoventral flexion and extension, axial rotation and lateral bending. Using the standard right-handed Cartesian coordinate system, these movements may be defined as rotation about the x, y and z axes respectively. Except in cases of intervertebral fusion, all three types of movement occur in each joint complex of the equine back. The greatest amount of dorsoventral movement takes place at the lumbosacral and the first thoracic intervertebral joints. The greatest amount of axial rotation and lateral bending was measured in the mid-thoracolumbar spine at the level of the 11th or 12th thoracic intervertebral joints. The caudal thoracic and the lumbar spine is the least mobile region of the equine back. In the mid-thoracic spine, lateral bending was always accompanied by a "coupled" axial rotation. The presence of the rib cage stabilised the cranial thoracic vertebrae against axial rotation.